A Phase 1a/1b Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients With Advanced or Metastatic Solid Tumors

The main objective for part 1a of the study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of oral TACH101 in participants with advanced and metastatic solid tumors. For part 1b, the main objective is the objective response rate (ORR) as assessed by radiographic progression measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

开始日期2023-02-17

申办/合作机构

Tachyon Therapeutics, Inc.

100 项与 Zavondemstat 相关的临床结果

登录后查看更多信息

100 项与 Zavondemstat 相关的转化医学

登录后查看更多信息

100 项与 Zavondemstat 相关的专利（医药）

登录后查看更多信息

项与 Zavondemstat 相关的文献（医药）

2010-12-01·The Journal of pharmacology and experimental therapeutics3区 · 医学

Dexmedetomidine Induces Both Relaxations and Contractions, via Different α₂-Adrenoceptor Subtypes, in the Isolated Mesenteric Artery and Aorta of the Rat

3区 · 医学

Article

作者: Ng, Kwok F. J. ; Wong, Emily S. W. ; Vanhoutte, Paul M. ; Man, Ricky Y. K.

Dexmedetomidine is an α(2)-adrenoceptor agonist and anesthetic. The present study was designed to characterize the receptor subtypes and the downstream mechanisms of the vascular effects of dexmedetomidine in small (mesenteric artery) and large (aorta) arteries ex vivo. Isometric tension was measured in Sprague-Dawley rat mesenteric and aortic rings (with or without endothelium). To study relaxations, cumulative concentrations of dexmedetomidine, 5-bromo-N-(2-imidazolin-2-yl)-6-quinoxalinamine, (UK14304), or clonidine were added to rings contracted with 9,11-dideoxy-9α,11α-methanoepoxy prostaglandin F(2α) (U46619) in the presence or absence of indomethacin; N(ω)-nitro-l-arginine methyl ester hydrochloride (l-NAME); 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole maleate (BRL44408); 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC239); l-657,743, (2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethyl-spiro[2H-benzofuro[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one hydrochloride hydrate (MK912); rauwolscine; prazosin; or pertussis toxin. To study contractions, dexmedetomidine was added to quiescent rings without endothelium or after incubation with l-NAME, rauwolscine, prazosin, indomethacin, or 3-[(6-amino-(4-chlorobenzensulfonyl)-2-methyl-5,6,7,8-tetrahydronaphth)-1-yl]propionic acid (S18886). Dexmedetomidine evoked relaxation at low concentrations (10 pM-30 nM) followed by contraction at higher concentrations (>30 nM) in the mesenteric artery. In the aorta, the relaxation was significantly smaller. The relaxation to dexmedetomidine depended on nitric oxide, endothelium, and G(i) protein, and it was mediated by α(2A/D)-adrenoceptors and possibly α(2B)-adrenoceptors. The contraction was mediated mainly by α(2B)- and α(1)-adrenoceptors and involved the action of prostanoids. UK14304 and clonidine induced greater and smaller relaxations, respectively, than dexmedetomidine. In conclusion, depending on the concentration used and the presence of functional endothelium, dexmedetomidine may evoke both relaxation and contraction in isolated arteries. The vascular effects also vary depending on the blood vessel studied. Its vascular effect is different from that of clonidine and UK14304.

Anti-cancer drugs

TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase

Article

作者: Chandhasin, Chandtip ; Stafford, Jeffrey A. ; Del Rosario, Joselyn ; Chen, Young K. ; Perabo, Frank ; Dang, Van ; Clarke, Michael ; Filvaroff, Ellen

Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones H3K9, H3K36, and H1.4K26. KDM4 overamplification or dysregulation has been reported in various cancers and has been shown to drive key processes linked to tumorigenesis, such as replicative immortality, evasion of apoptosis, metastasis, DNA repair deficiency, and genomic instability. KDM4 also plays a role in epigenetic regulation of cancer stem cell renewal and has been linked to more aggressive disease and poorer clinical outcomes. The KDM4 family is composed of four main isoforms (KDM4A-D) that demonstrate functional redundancy and cross-activity; thus, selective inhibition of one isoform appears to be ineffective and pan-inhibition targeting multiple KDM4 isoforms is required. Here, we describe TACH101, a novel, small-molecule pan-inhibitor of KDM4 that selectively targets KDM4A-D with no effect on other KDM families. TACH101 demonstrated potent antiproliferative activity in cancer cell lines and organoid models derived from various histologies, including colorectal, esophageal, gastric, breast, pancreatic, and hematological malignancies. In vivo, potent inhibition of KDM4 led to efficient tumor growth inhibition and regression in several xenograft models. A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.

项与 Zavondemstat 相关的新闻（医药）

2023-03-01

·BioSpace

Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors

SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase 1 clinical study of TACH101 in patients with advanced solid tumors, with an expansion phase planned for gastrointestinal cancers, including microsatellite instability high (MSI-H) colorectal cancer (CRC). TACH101 is a first-in-class, small molecule inhibitor of KDM4 histone demethylase, an important epigenetic regulator of processes responsible for proliferation of cancer stem cells, evasion of apoptosis, and deficiency in DNA repair. Through KDM4, TACH101 inhibits proliferation of cancer stem cells and solid and hematopoietic tumors shown in various preclinical and animal models. Tachyon has received clearance of the Company’s Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to develop TACH101 for the treatment of advanced cancers. "Therapy resistance and metastatic dissemination are the main challenges in developing effective cancer treatments. Cancer stem cells and tumor-initiating cells play a significant role in this, and until now, have only been poorly characterized. We have completed extensive preclinical studies to support the clinical advancement of TACH101, and we have shown its ability to reduce the population of tumorigenic cells and potently shrink tumors in cancer models,” said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapeutics. “We are pleased to receive the support of CIRM to advance the first KDM4 inhibitor to enter clinical development.” “We are excited to fund Tachyon’s first clinical trial with TACH101, the first KDM4 inhibitor in clinical development,” states Dr. Maria T. Millan, President and Chief Executive Officer, California Institute for Regenerative Medicine (CIRM). ”Consistent with CIRM’s mission to accelerate transformative stem-cell based approaches to address unmet medical needs, this candidate is a potential breakthrough approach to targeting cancer stem cells, which drive aggressive and hard to treat cancers.” About Tachyon Therapeutics, Inc. Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to propel new options for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance our programs with speed, innovation, quality and scientific integrity. For more information, please visit . About CIRM At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today’s most promising stem cell technologies. With $5.5 billion in funding and more than 150 active stem cell programs in our portfolio, CIRM is the world’s largest institution dedicated to helping people by bringing the future of cellular medicine closer to reality. For more information go to .

临床申请临床1期

2023-03-01

·BioSpace

Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

- First patient enrolled in Phase 1 clinical study of TACH101, a small molecule, KDM4 histone demethylase inhibitor, in patients with advanced or metastatic solid tumors - Tachyon also announces the appointment of Jeff Stafford, Ph.D., to the Company’s Board of Directors SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today announced the closing of a financing that brings the Company’s total equity financing raises to $11.6 million and, together with a recently announced CIRM grant of $7.1 million, brings total funding in the Company to $18.7 million since the Company started operations in 2020. The round includes new investors, Veblen Ventures, Khosla Ventures, and Red Tree Venture Capital, and existing investors, demonstrating their continued commitment to supporting Tachyon's potential. Proceeds from the financing are being used to run the Phase 1 clinical study in advanced solid tumors for TACH101, a first-in-class, small molecule, KDM4 histone demethylase inhibitor, as well as to advance the Company’s pipeline of emerging oncology drug candidates targeting previously unexplored mechanisms of tumorigenesis. “The Tachyon team are enabling new frontiers in targeted oncology by developing cancer therapies that address fundamental drivers of tumorigenesis,” commented Heath Lukatch, Ph.D., Managing Director of Red Tree Venture Capital. “We look forward to supporting the team as they work towards transforming the treatment paradigms for advanced and metastatic solid tumors.” “This new capital, from a committed and distinguished investor syndicate that includes new and existing investors as well as the grant from CIRM, highlights the progress we’ve made to bring our lead program into the clinic,” said Frank Perabo, M.D. Ph.D., Chief Executive Officer of Tachyon. Founded on the scientific work of Drs. Stephen Quake and Michael Clarke at Stanford University, Tachyon Therapeutics is developing novel, first-in-class therapeutics that target pathways to fight cancer at its core tumorigenic mechanisms. In November 2019, Tachyon received an exclusive license to research, develop, and commercialize products for small molecule inhibitors of KDM4 including TACH101 (formerly QC8222) from Celgene Quanticel Research, Inc, now Bristol Myers Squibb, Summit, NJ. The Company recently received clearance of the Company’s Investigational New Drug (IND) application for TACH101 and enrolled its first patient in a Phase 1 clinical study in patients with advanced or metastatic solid tumors (ClinicalTrials.gov Identifier NCT05076552). “The start of our first clinical trial for TACH101, our lead program, is a significant milestone for the company as we strive to bring promising new therapeutics to patients who are fighting advanced cancers,” continued Dr. Perabo. “We are also pleased to welcome to our Board of Directors, Dr. Jeff Stafford, who has decades of experience in developing innovative small molecule therapeutics against novel cancer targets and led the initial discovery and development of our novel KDM4-inhibitor, TACH101.” Dr. Stafford is the President and CEO of 858 Therapeutics. Prior to this, he was the founding CSO of Quanticel Pharmaceuticals (acquired by Celgene), where his team discovered TACH101 from a single cell genomics platform for precision targeting of cancer stem cells. Dr. Stafford has also held senior scientific and management positions at Takeda and GlaxoSmithKline and was the founding CEO of Jecure. Dr. Stafford’s discovery teams have been responsible for the discovery of three FDA-approved drugs – Votrient™ (pazopanib), Nesina™ (alogliptin), and Byfavo™ (remimazolam) – and several others currently in clinical trials. About Tachyon Therapeutics Inc. Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to propel new options for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance our programs with speed, innovation, quality and scientific integrity. For more information, please visit .

临床1期高管变更临床申请

2022-08-26

·药明康德

一周盘点 | 多款新型细胞疗法步入临床，基因疗法剑指遗传性神经退行性疾病...

▎药明康德内容团队编辑本期看点用于治疗亨廷顿氏病的新型腺相关病毒基因疗法BV-101在法国获批可开展1/2期临床试验。具有四种强大且互补功能的CAR-iNK细胞疗法CNTY-101的IND申请获得FDA许可。尤因肉瘤新型可逆LSD1抑制剂seclidemstat将把妙佑医疗国际的两个站点添加到其正在进行的1/2期临床试验中。药明康德内容团队整理制图BV-101：在法国获批开展1/2期临床试验BV-101是一种基于专门设计的腺相关病毒（AAV）载体开发的基因疗法，被开发用于治疗亨廷顿氏病。亨廷顿氏病是一种遗传性神经退行性疾病，由亨廷顿基因的异常重复突变导致神经细胞中异常的蛋白质聚集引起，症状通常发生于30至50岁的成年人，也可能更早。BV-101可以同时解决病变神经元的代谢功能障碍，并有助于清除突变的亨廷顿蛋白。通过MRI引导的神经外科技术，可以针对大脑基底核结构中的目标组织进行BV-101的给药。在临床前研究中，给小鼠递送表达CYP46A1（一种大脑中的关键酶，在亨廷顿氏病的患者中减少）的转基因的BV-101能够修复小鼠的基本胆固醇通路、提供神经保护并恢复身体机能。BV-101于2019年被欧洲药品管理局授予孤儿药资格。即将开展的1/2期临床试验是一项开放标签、剂量递增研究，以评估BV-101对患有早期亨廷顿病的成年受试者的安全性、耐受性和初步疗效。CNTY-101：IND申请获得FDA许可 CNTY-101是一种在研现货型的癌症免疫治疗候选产品，利用诱导多能干细胞（iPSC）衍生的自然杀伤（NK）细胞和靶向CD19的嵌合抗原受体（CAR）组成CAR-iNK细胞疗法。根据Century Therapeutics的新闻稿，CNTY-101是首个具有四种强大且互补功能的候选同种异体细胞治疗产品。除了能够靶向CD19，通过借助Century公司的核心技术Allo-Evasion，CNTY-101还能够克服宿主与移植物排斥的三种主要途径——CD8+ T细胞，CD4+ T细胞和NK细胞。此外，CNTY-101还能表达IL-15，从而改善其功能和持久性。为了提高其安全性，iNK细胞还被设计携带EGFR安全开关。概念验证研究表明，通过给予已获FDA批准的EGFR靶向药西妥昔单抗可以快速消除细胞。即将开展的1期试验ELiPSE-1（NCT05336409）旨在评估CNTY-101在复发或难治性CD19阳性B细胞恶性肿瘤患者中的安全性，耐受性，药代动力学和初步疗效。Seclidemstat：增加1/2期临床试验站点Seclidemstat是一种新型口服赖氨酸特异性去甲基化酶1（LSD1）抑制剂，被开发用于治疗尤因肉瘤和FET重排的肉瘤。在尤因肉瘤患者中，由于染色体易位，常常会出现一种高度无序且很难直接靶向的致癌性蛋白——EWS/ETS融合蛋白。LSD1是一种能与EWS/ETS融合蛋白相互作用的表观遗传酶，常在癌细胞中高表达。Seclidemstat能够通过阻断EWS/ETS融合蛋白与LSD1酶的结合，逆转异常基因的表达。此外，由于LSD1是细胞稳态所必需的，因此不可逆地抑制这种蛋白质会导致不良反应（如血液学毒性）。而seclidemstat能够可逆地绑定到LSD1，使其能够维持一定的功能。临床前研究显示，seclidemstat可以减缓/停止尤因肉瘤肿瘤的生长。Seclidemstat目前已获得了美国FDA授予的孤儿药资格、罕见儿科疾病资格（Rare Pediatric Disease Designation）和快速通道资格。近期，其开发机构Salarius Pharmaceuticals宣布，将把妙佑医疗国际的两个站点添加到其正在进行的1/2期临床试验中。KTX-1001：IND申请获得FDA许可KTX-1001是一种在研的组蛋白甲基转移酶SET结构域（称为MMSET）的小分子甲基转移酶抑制剂，MMSET是多发性骨髓瘤染色质结构和转录的主要调节器。MMSET由于t（4；14）易位而在最高达20%的多发性骨髓瘤（MM）患者中高表达。据官网资料介绍，KTX-1001能够抑制MMSET的转录，减少甲基化并关闭多发性骨髓瘤细胞癌变所需的基因的表达。此次即将启动的1期临床试验旨在确定KTX-1001在具有t（4；14）易位的复发和难治性多发性骨髓瘤患者中的安全性、耐受性和初步疗效。Imetelstat：1期临床试验完成首例患者给药Imetelstat是一种潜在“first-in-class”端粒酶抑制剂，被开发用于血液系统恶性肿瘤。此前的2期临床试验数据显示，imetelstat通过靶向端粒酶能够抑制骨髓血液系统恶性肿瘤中恶性干细胞和祖细胞不受控制的增殖，从而导致恶性细胞的凋亡，并具有可能恢复正常的造血功能。Imetelstat已被FDA授予快速通道资格，用于治疗特定骨髓增生异常综合征（MDS）患者，以及经JAK抑制剂治疗后复发或难治的中度2级或高危骨髓纤维化（MF）患者。目前开展的1期临床研究IMproveMF是一项imetelstat联合ruxolitinib一线治疗中度2级或高危MF患者的单臂、开放标签研究，目前已完成了首例患者给药。SynKIR-110：向FDA递交IND申请SynKIR-110是一种基于杀伤性免疫球蛋白样受体（KIR）-CAR平台技术的双链CAR-T细胞疗法。这种KIR-CAR能够自然地与DAP12蛋白相互作用，向T细胞传递重要的信号，促进T细胞增殖、细胞因子分泌和细胞毒性。临床前研究表明，与当前FDA批准的经典的第二代CAR设计的T细胞相比，这些将KIR-CARs引入T细胞而制造的SynKIR-T细胞能够更有效地消除体内的侵袭性肿瘤。Verismo Therapeutics已向FDA递交了IND申请，要求批准在表达间皮素的卵巢癌、间皮瘤和胆管癌患者中启动SynKIR-110的首次人体1期临床试验。RECCE 327（R327）：公布来自1期临床试验的积极安全数据R327是一种广谱合成聚合物抗感染药物，旨在解决严重或危及生命的细菌感染，包括脓毒症。研究表明，该化合物能够迅速且不可逆地关闭细菌细胞能量ATP的产生，使细菌的蛋白质合成减少和细胞膜去极化，在较高浓度下甚至可以导致细胞裂解。R327已被FDA授予快速通道资格。此次公布的1期临床试验的第7组显示，在1小时内静脉给药6000 mg（比第1组50 mg的剂量增加了120倍）在10名健康男性受试者中没有表现出严重的不良反应，建议启动第8组试验。CUE-102：1期临床试验完成首例患者给药CUE-102是一种由两个呈递Wilms肿瘤1（WT1）肽的人白细胞抗原（HLA）分子、四个亲和力减弱的IL-2分子和一个效应减弱的人免疫球蛋白G（IgG1）Fc结构域组成的新型生物制品，被开发作为单一疗法治疗WT1阳性复发/转移性癌症患者。WT1是一种公认的癌胎蛋白，已知在多种实体瘤和血液系统恶性肿瘤中过度表达，包括胃癌、胶质母细胞瘤、胰腺癌、卵巢癌、子宫内膜癌、乳腺癌、肺癌、结直肠癌和急性髓系白血病等。Cue Biopharma表示，针对CUE-102的研究最初将集中在结直肠癌、胃癌、胰腺癌和卵巢癌上。PT199：1期临床试验完成首例患者给药PT199是一种能够完全抑制可溶性和膜结合的CD73的抗CD73单克隆抗体。与其他一些表现不完全抑制作用的CD73抑制剂不同，PT199解决了当前CD73抑制剂的局限性，有望增加抗肿瘤免疫激活，对抗腺苷介导的免疫抑制性肿瘤微环境（TME）。目前，PT199的多中心1期临床试验正在评估PT199单独或与PD-1抑制剂联合用于已进展的局部晚期或转移性实体瘤患者的安全性、耐受性、药代动力学、药效学和初步疗效，并已完成了首例患者给药。Lanraplenib：1b/2期临床试验完成首例患者给药Lanraplenib是一种靶向脾酪氨酸激酶（SYK）的下一代选择性抑制剂，用于治疗复发/难治性FLT3突变急性髓细胞白血病（AML）患者。在临床前研究中，lanraplenib被证明对NPM1突变和FLT3突变的AML样本具有抗白血病活性。目前开展的1b/2期临床试验是一项lanraplenib联合gilteritinib治疗复发/难治性FLT3突变AML患者的多中心、开放标签、剂量递增研究，目前已完成了首例患者给药。NTLA-2002：即将公布1/2期临床试验的中期数据NTLA-2002是一种研究性的体内CRISPR/Cas9疗法，旨在关闭激肽释放酶B1（KLKB1）基因的表达，该基因编码前激肽释放酶前体蛋白。NTLA-2002目前作为一种单剂量疗法正在开展一项用于预防遗传性血管性水肿（HAE）患者的疾病发作的1/2期研究。该研究正在评估NTLA-2002在1型或2型HAE成人患者中的安全性、耐受性、药代动力学和药效学，将于近期公布相关中期数据。DC-6001：IND申请获得FDA许可DC-6001是一种由两种抗CD93单克隆抗体组成的研究性新药。这两种单克隆抗体具有不同的体内和体外特性，并在临床前研究中展现出能够阻断CD93不同表位的能力。CD93是一种新的靶点，已被证明在肿瘤血管系统的异常发展中发挥着关键的作用。CD93功能障碍通常会使肿瘤微环境缺氧，并影响癌症治疗（包括检查点抑制剂）的疗效。此次即将开展的1期临床研究将评估DCBY02在患有各种晚期癌症的成年患者中的安全性和有效性。TACH101：IND申请获得FDA许可TACH101是一种有效的、选择性的小分子KDM4抑制剂，也是一种新型的表观遗传候选药物。KDM4是肿瘤发生的关键驱动因素和癌症治疗的新靶点，可控制基因表达、细胞增殖、干细胞维持、细胞凋亡和转移。其过表达与许多癌症类型有关，包括乳腺癌、结直肠癌、食管癌、前列腺癌和淋巴瘤等。目前，Tachyon Therapeutics正在开发TACH101用于治疗晚期或转移性癌症。Baxdrostat（CIN-107）：即将公布1期临床试验数据Baxdrostat（CIN-107）是一种高选择性的口服小分子醛固酮合酶抑制剂，作用于肾素-血管紧张素-醛固酮调节系统，用于治疗耐药性高血压和原发性醛固酮增多症。临床研究数据显示，CIN-107具有良好的安全性和耐受性，以及抑制醛固酮的特异性，能够明显降低人体内醛固酮含量。近期，其开发机构CinCor Pharma将公布其随机、安慰剂对照、多剂量爬坡（MAD）1期研究的临床数据，该研究评估了健康志愿者中baxdrostat的安全性、药代动力学和药效学。药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息参考资料： [1] BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease. Retrieved August 23, 2022, from https://www.askbio.com/brainvectis-a-subsidiary-of-askbio-receives-clearance-to-conduct-phase-i-ii-clinical-trial-in-france-for-its-novel-gene-therapy-for-early-stage-huntingtons-disease/[2] Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection. Retrieved August 25, 2022, from https://investors.centurytx.com/news-releases/news-release-details/century-therapeutics-receives-study-may-proceed-notification-fda[3] K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001. Retrieved August 23, 2022, from https://www.prnewswire.com/news-releases/k36-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-and-formation-of-clinical-advisory-board-for-lead-program-ktx-1001-301610149.html[4] DynamiCure Announces IND Clearance to Advance First Antibody Candidate from its DC-6001 Anti-CD93 Program into Clinical Development. Retrieved August 22, 2022, from https://dynamicure.com/newsroom/dynamicure-announces-ind-clearance-to-advance-first-antibody-candidate-from-its-dc-6001-anti-cd93-program-into-clinical-development/[5] Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 InhibitorTACH101 for Advanced Solid Tumors. Retrieved August 24, 2022, from https://tachyontx.com/wp-content/uploads/2022/08/Tachyon-IND-2022-Press-Release_FINAL.pdf[6] Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110, a KIR-CAR T-cell Immunotherapy Candidate. Retrieved August 19, 2022, from https://www.prnewswire.com/news-releases/verismo-therapeutics-announces-submission-of-ind-application-to-the-fda-for-synkir-110tm-a-kir-car-t-cell-immunotherapy-candidate-301609162.html[7] Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers. Retrieved August 22, 2022, from https://www.cuebiopharma.com/investors-media/news/[8] Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors. Retrieved August 23, 2022, from https://www.phanesthera.com/news/phanes-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-pt199-for-advanced-solid-tumors/[9] Kronos Bio Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Lanraplenib in Combination with Gilteritinib in Acute Myeloid Leukemia. Retrieved August 22, 2022, from https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-first-patient-dosed-phase-1b2-clinical[10] Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis. Retrieved August 22, 2022, from https://ir.geron.com/investors/press-releases/press-release-details/2022/Geron-Announces-First-Patient-Dosed-in-IMproveMF-Phase-1-Combination-Study-in-Frontline-Myelofibrosis/default.aspx[11] Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327. Retrieved August 23, 2022, from https://www.globenewswire.com/news-release/2022/08/23/2502906/0/en/Recce-Pharmaceuticals-Announces-Positive-Safety-Data-from-Seventh-Cohort-of-Phase-1-Clinical-Trial-Evaluating-Healthy-Subjects-Intravenously-Dosed-with-RECCE-327.html[12] Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium. Retrieved August 23, 2022, from https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-present-interim-clinical-data-ongoing-0[13] CinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 Congress. Retrieved August 23, 2022, from https://www.cincor.com/news-releases/news-release-details/cincor-pharma-announces-presentation-phase-1-clinical-data[14] Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas. Retrieved August 22, 2022, from https://investors.salariuspharma.com/news-releases/news-release-details/salarius-pharmaceuticals-adds-two-mayo-cli免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

基因疗法细胞疗法免疫疗法抗体小分子药物

100 项与 Zavondemstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期癌症	临床1期	美国	Tachyon Therapeutics, Inc.	2023-02-17
晚期恶性实体瘤	临床1期	美国	Tachyon Therapeutics, Inc.	2023-02-17
转移性实体瘤	临床1期	美国	Tachyon Therapeutics, Inc.	2023-02-17
血液肿瘤	临床前	美国	Tachyon Therapeutics, Inc.	2020-09-09

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


TACH101 (ESMO2021)	N/A	三阴性乳腺癌	-	TACH101	顧網淵繭蓋願鏇蓋蓋壓(夢壓顧網觸願積願積築) = 構襯築網鏇醖獵鬱鹽鑰範艱遞鬱顧構積餘獵淵 (網壓壓壓窪蓋憲網憲簾 ) 更多	-	2021-09-16